Anyah Settle

Explore & develop bioanalytical methodologies to monitor the physical stability of co-formulated drug product

About me

I completed my MChem degree at The University of Sheffield in 2022, undertaking research with Dr Jim Reid. This project involved investigating the activity of fluorescent proteins with applications in fluorescent imaging. Throughout the project, I synthesised, purified, and tested multiple fluorescent proteins to investigate their photochemical properties. This project gave me a greater insight into chemical biology and has motivated me to pursue this area further.  My current project builds upon my interest in this area as I am investigating the physical-chemical properties and characterisation of co-formulations of biological therapeutics (biologics). This project excites me as it has industrial applications due to the development of biological co-formulations of two different biologics being a relatively unexplored area. This is also an area which, in the future, may benefit patients with the development of new formulations.

My project

I am currently studying under Dr Barbara Ciani and Prof. Tuck Sen Wong in the departments of Chemistry and Chemical and Biological Engineering at The University of Sheffield and in partnership with AstraZeneca. This project involves developing an analytical workflow to characterise biologics via a combination of analytical techniques. The biologics investigated will be a combination of monoclonal antibodies and peptides in a single formula, known as co-formulation. Characterisation methods to be utilised are SEC-MALS-DLS, AF4-MALS-DLS and CG-MALS-DLS. By combining such techniques, we will be able to develop a more comprehensive analytical fingerprint of both individual components and, ultimately, co-formulations. The stability of individual components and co-formulations will also be investigated to assess the effects co-formulation has on the individual components. Co-formulation has commercial benefits as a single formulation of multiple pharmacologically active compounds reduces the physical and time resources in a clinical setting. This also has patient-focused benefits as patients will only require one administration of a co-formulation compared to multiple administrations of single biologics.